Zentalis' Data From Part 1 Of MUIR Trial Focusing On Azenosertib In Combination With Paclitaxel In Platinum-Resistant Ovarian Cancer Accepted For Presentation At ASCO 2026

Benzinga Newsdesk www.benzinga.com Neutral 74.6%

Neg 0% Neu 74.6% Pos 0%

Comments

No comments yet. Be the first!